HC Wainwright Rates Alnylam Pharmaceuticals (ALNY) buy
HC Wainwright maintains its buy rating on Alnylam Pharmaceuticals with a $470 price target, a 57.67% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Alnylam Pharmaceuticals, Inc. ($ALNY) "buy" with a $470 price target on June 29, 2026.
Since the rating, $ALNY is up 6.7% after 1 week, down 2.4% after 1 month and down 21.0% to date (from the $293.52 close on Jun 29, 2026).
ALNY
Alnylam Pharmaceuticals, Inc.
Key Points
- HC Wainwright reiterated its buy rating on Alnylam Pharmaceuticals, Inc. (ALNY) with a price target of $470 on June 29, 2026.
- HC Wainwright's $470 price target implies 57.67% upside from Alnylam Pharmaceuticals, Inc.'s ($ALNY) current $298.10 share price.
- Shares of NasdaqGS:ALNY traded near $291.37 on Monday, with a market cap of approximately $38.9 billion and a forward P/E of 21.17.
- Insiders and analysts show varied activity with recent insider purchases and multiple buy ratings from firms like Citigroup and RBC Capital.
Get $ALNY trade alerts by text
We text you when insiders, Congress or big funds trade $ALNY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Alnylam Pharmaceuticals, Inc. alert may contain errors. Disclosures
On June 29, 2026, HC Wainwright reiterated its buy rating on Alnylam Pharmaceuticals, Inc. (NasdaqGS: ALNY), setting a price target of $470. The analyst Patrick R. Trucchio maintained the positive outlook, suggesting confidence in the company's future performance.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Alnylam Pharmaceuticals, Inc. Stock Up 24.4%
Shares of NasdaqGS:ALNY traded near $291.37 on Monday. Alnylam Pharmaceuticals, Inc. has a market capitalization of approximately $38.9 billion. The company's P/E ratio stands at 73.03, with a forward P/E of 21.17, indicating expectations of higher earnings growth. The stock has experienced a 52-week range from $273.11 to $495.55, with a 50-day moving average of $296.63 and a 200-day moving average of $370.21. The company has a current ratio of 3.13, a quick ratio of 2.89, and a debt-to-equity ratio of 276.20.
$ALNY price target
Alnylam Pharmaceuticals, Inc. daily closes and this analyst's $470 target. Not advice.
Recent Earnings
Alnylam Pharmaceuticals reported revenue of approximately $4.29 billion, showing a robust growth of 96.4%. The company achieved a net margin of 12.55% and a return on equity of 90.36%. The next earnings report is expected on July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 56.5%. Revenue beat estimates by 2.7%.
-
Profit surprise
EBITDA missed by 5 percent. Operating income beat by 55 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin down 6.1 points. Operating margin up 20.0 points. Negative free cash flow.
Earnings Call Summary
Alnylam delivered 1.17 billion dollars in total product revenue in the first quarter, marking its first quarter exceeding 1 billion dollars. The TTR franchise generated 910 million dollars, up 153 percent year over year, with U.S. revenue growing 230 percent driven by strong AMVUTTRA adoption for heart disease. Management highlighted over 90 percent patient adherence to vutrisiran and broader international success including new launches in Europe and Japan, though Germany pricing adjustments created a temporary headwind that they expect to reverse in coming quarters.
Guidance Management reaffirmed full year guidance of 4.4 to 4.7 billion dollars in TTR revenue, expecting significantly higher quarter-over-quarter growth for the rest of 2026. They also expect the rare disease portfolio to continue contributing steady growth alongside the TTR cardiomyopathy launch expansion in international markets.
Negative report. Results or guidance disappointed and expectations are likely to move lower.
Insider Buying and Selling at Alnylam Pharmaceuticals, Inc.
Recent insider activity at Alnylam Pharmaceuticals includes several transactions on June 1, 2026. David Pyott purchased 3,830 shares and sold the same amount under a planned transaction. Benjamin Cravatt acquired 4,393 shares, while Amy Schulman and Olivier Brandicourt bought 838 and 1,441 shares, respectively.
Analysts Set New Price Targets
On June 29, 2026, HC Wainwright & Co. maintained its buy rating on Alnylam Pharmaceuticals with a $470 price target. Citigroup initiated coverage with a buy rating and a $380 target on May 19, 2026. RBC Capital maintained its buy rating with a $445 target, and Truist Securities set a $505 target while maintaining a buy rating.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biotechnology company based in Cambridge, Massachusetts. Founded in 2002, the company focuses on discovering, developing, and commercializing therapeutics based on ribonucleic acid interference (RNAi). Alnylam offers several products for conditions such as amyloidosis, hypercholesterolemia, and hemophilia, and is developing treatments for a wide range of diseases, including hypertension, myasthenia gravis, and Alzheimer's disease. The company collaborates with industry leaders like Regeneron, Roche, and Sanofi.
Bottom Line
HC Wainwright's reiteration of a buy rating and a $470 price target underscores confidence in Alnylam Pharmaceuticals' growth prospects. Investors closely watch such analyst updates for insights into potential stock performance. As always, remember that analyst ratings and 13F filings are backward-looking and may not reflect current market conditions.
Related Filing Alerts
Source: HC Wainwright's rating change on $ALNY (Jun 29, 2026). Written by software, not financial advice. How we make alerts